Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Olysio

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Olysio was produced by Janssen.

The end of hepatitis C?

The end of hepatitis C? The launch of drugs such as Gilead's Sovaldi (sofosbuvir) and Harvoni (sofosbuvir and ledipasvir), AbbVie's Viekirax (ombitasvir/paritaprevir/ritonavir) and Exviera (dasabuvir), J&J's Olysio (simeprevir) and

Gilead's Sovaldi wins NICE approval but faces access delay

Gilead's Sovaldi wins NICE approval but faces access delay The Institute also recommends Janssen's hepatitis C drug Olysio.  . NICE has issued final guidance recommending two new innovative hepatitis C drugs - Gilead's Sovaldi (sofosbuvir) and Janssen's Olysio (simeprevir) - ... Meanwhile, Janssen's Olysio has

Merck’s hep C drug no longer a ‘breakthrough’

Merck’s hep C drug no longer a ‘breakthrough’ Other new hepatitis C treatments include AbbVie's Viekira Pak and Janssen's Olysio (simeprevir).

J&J chief predicts 10 new pharma filings by 2017

J&J chief predicts 10 new pharma filings by 2017 Exchange rates took a toll on overall sales, but pharma shrugged that off thanks to a surge in Olysio sales to $321m from $23m in the fourth quarter of 2013, with ... Olysio drove growth in 2014 but will come under pressure from new HCV therapies such as

NICE backs new hepatitis C treatments

NICE backs new hepatitis C treatments Gilead Sciences' Sovaldi (sofosbuvir) and Janssen's Olysio (simeprevir) to treat people with the infection. ... Both drugs were approved in Europe in 2014 based on impressive clinical data and have gone on to record substantial sales, helped by the fact

[ Previous 5 results ] 1 2 3 4 5 6 7 8 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....